Drugs / Elbasvir/Grazoprevir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02940496 | Dec 2016 → Aug 2023 | hepatitis C virus infection, hepatocellular carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elbasvir/Grazoprevir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02940496 ↗ |
| Route | Oral | “Given PO” NCT02940496 ↗ |